NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Lexaria Bioscience Corp. (LEXX) Stock Analysis

Lexaria Bioscience Corp. (LEXX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LEXX

$2.82

+$0.17 (+6.42%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LEXX with… →

LEXX Key Statistics

As of Oct 21, 2026
Trading
Open
$2.68
Previous Close
$2.65
Day's Range
2.52–2.89
52-Week Range
2.43–21.60
Volume
28.67K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.60
Valuation
Market Cap
$5.94M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
30.62
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.10
Financials (FY)
Revenue (FY)
$705.92K+52.05%
Net Income (FY)
−$11.90M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.11M
1-Year Return
−79.27%
Dividend and dates
Avg Volume
73.05K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LEXX closed at $2.82, −79.27% over 1 year.

Lexaria Bioscience Corp. (LEXX) has a market capitalization of $5.94M.

In fiscal 2025, LEXX reported revenue of $705.92K.

LEXX Stock Return by Calendar Year

Lexaria Bioscience Corp. (LEXX) return since Jan 2021: what $10,000 became

1 year
$10,000 $2,073
−79.27%
5 years
$10,000 $277
−97.23%
Since Jan 2021
$10,000 $420
−95.80%

If you had invested $10,000 in Lexaria Bioscience Corp. (LEXX) at the close on January 12, 2021, the earliest close on record here, it would have been worth $420 at the close on October 21, 2026: −95.80% in total, −42.27% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−69.53%
2025−70.62%
2024+68.00%
2023−49.19%
2022−38.96%
2021−10.04%

As of October 21, 2026.

LEXX Revenue and Earnings by Fiscal Year

FY ends August
Fiscal yearRevenueNet incomeNet margin
2025$705.92K−$11.90M−1,686.0%
2024$464.28K−$5.80M−1,248.2%
2023$226.21K−$6.66M−2,946.4%
2022$255.40K−$7.27M−2,846.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$705.92K$703.20K−$11.88M−$11.90M−1,686.0%
2024$464.28K$459.46K−$5.75M−$5.80M−1,248.2%
2023$226.21K$194.71K−$6.53M−$6.66M−2,946.4%
2022$255.40K$183.56K−$6.62M−$7.27M−2,846.3%

Annual figures as reported, in the company's reporting currency. As of August 31, 2025.

LEXX Valuation vs Biotechnology Median

Median of 608 stocks
MetricLEXXBiotechnology medianvs median
P/S ratio30.6213.30130% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Lexaria Bioscience Corp. (LEXX) at $5.94M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 7 employees.

LEXX last closed at $2.82 on October 21, 2026. That is +$0.17 (+6.42%) against the previous close. The 52-week range on file runs from $2.43 to $21.60. The latest close sits 16.05% above that 52-week low.

Financial Health

In fiscal 2025, Lexaria Bioscience Corp. reported revenue of $705.92K. Against the prior fiscal year total of $464.28K, that is a change of +52.05%. The same year closed with a net loss of $11.90M. Trailing earnings per share are −5.1.

Across the 4 fiscal years on file, revenue moves from $255.40K in 2022 to $705.92K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 30.62 times revenue. On price-to-sales that is 130.26% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −79.27%. Measured over 5 years, that is −51.18% a year compounded. The reported beta is 0.6. Annualized volatility over the trailing 5 years is 99.98%.

Growth & Income

The record shows no dividend for LEXX.

Across the complete calendar years on file, 2024 returned +68.00% and 2025 returned −70.62%. Of the 5 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −69.53% year to date.

Peer Comparison

Lexaria Bioscience Corp. (LEXX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lexaria Bioscience Corp. LEXX $5.94M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Lexaria Bioscience Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Visit website →